The expression of stem cell‐related indicators as a prognostic factor in human lung adenocarcinoma

Zhang, Xueyan; Dong, Qian; Huang, Jinsu; Huang, Aimi; Shi, Chunlei; Jin, Bo; Sha, Hao; Feng, Jiaxuan; Geng, Qin; Zhou, Jin; Xu, Haoping; Han, Baohui

doi:10.1002/jso.21718

Cited by 21 publications

(21 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bmi-1 is known to be a key regulator in the self-renewal of stem cells [36], and a recent report has shown that the expression of Bmi-1 in surgically resected specimens was a significant prognostic factor of a poor outcome in lung adenocarcinoma [20]. In our study, no obvious relation was seen between the expression of ABCG2 or Bmi-1 and patient outcome.…”

Section: Discussioncontrasting

confidence: 70%

“…A previous study reported that the expression of some CSC-related markers was related to a poor prognosis among patients with initially resected NSCLC, suggesting their potential use as prognostic markers such as CD133, ATP-binding cassette 6 superfamily G member 2 (ABCG2), Bmi-1, and Octamer-4 [20][21][22]. Indeed, CSCs are known to have drug or radiation-resistant features [23,24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

et al. 2012

View full text Add to dashboard Cite

The expression of several cancer stem cell (CSC)-related markers has been confirmed in non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC-related markers in patients with NSCLC undergoing induction chemoradiotherapy (CRT). Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. The expressions of CSC related markers (CD133, ALDH1, ABCG2, and Bmi-1) were examined using immunohistochemical staining in surgically resected specimens. Among the 50 patients, 20 patients had no residual tumor cells in the resected specimen when examined pathologically; CSC-related marker expressions and their correlation to survival were evaluated in the other 30 patients. After a median follow-up period of 72 months, the 5-year overall survival rate of the patients with CD133-positive or ALDH1-positive specimens was significantly worse than that of the patients with both CD133-negative and ALDH1-negative expressions (44.9% vs. 90.0%, respectively; P = 0.042). In a multivariate analysis, CD133 and ALDH1 negativity (P = 0.047) and cN2-3 single station metastasis (P = 0.03) were significant independent prognostic factors for prolonged survival. The expressions of CSC-related markers after CRT were 3 significantly correlated with a poor prognosis in patients with NSCLC. The development of therapeutic strategies including adjuvant therapy that take CSC-related marker positivity into consideration is likely to be a key factor in further improvements of the prognosis of patients undergoing trimodality therapy.

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Introductionmentioning

confidence: 99%

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Expression of Oct4 is restricted to pluripotent cells and its level decreases with the onset of differentiation and loss of pluripotency (9,15). In recent studies, Oct4 expression has been detected in various carcinomas including breast, prostate, bladder, head and neck squamous cell carcinomas and lung adenocarcinoma, which correlates with an unfavorable prognosis (16)(17)(18)(19)(20). Oct4 expression was only found in the immature neuroepithelium of high-grade immature teratomas, which indicates that Oct4 may be a promising biomarker for the diagnosis of highly malignant immature teratoma (21).…”

Section: Discussionmentioning

confidence: 99%

Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy

Yang

Zheng

et al. 2012

Oncol Rep

View full text Add to dashboard Cite

Abstract. Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Oct4 and Sox2 are essential transcription factors for embryonic development and play key roles in determining the fate of stem cells. In this study, we aimed to investigate the expression of Oct4 and Sox2 in NB tissues, and evaluated their relationship with various clinicopathological parameters. Oct4 and Sox2 expression in 65 samples of NB and paracancerous tissues was examined by real-time PCR. The relationship between Oct4 and Sox2 expression and clinical data was assessed. To detect Oct4 and Sox2 expression at the protein level, western blot analyses and immunohistochemical staining were employed. We found that the expression levels of Oct4 and Sox2 in NB tissues were significantly higher than those in paracancerous tissues (P<0.05). Oct4 and Sox2 expression was significantly correlated to the clinical stage of NB, but not other clinicopathological parameters including patient gender and age, tumor size, location and histological classification. In stage III and IV tumors, Oct4 and Sox2 expression was significantly decreased in the chemotherapy subgroup as compared with that of the non-chemotherapy subgroup (P<0.05). These findings suggest that the expression of Oct4 and Sox2 may correlate with the genesis and progression of NB. In addition, Oct4 and Sox2 expression can be inhibited by chemotherapy.

show abstract

“…Likewise, BMI-1 expression has also been correlated with poorer patient outcomes [107, 121, 220], and amplification and concordant overexpression of the PcG, PHC3 , has recently been associated with poorer outcomes in NSCLC [221]. …”

Section: Prognostic Biomarkersmentioning

confidence: 99%

Epigenetics of lung cancer

Langevin

Kratzke

Kelsey

2015

Translational Research

140

103

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality in the United States. Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA expression, have widely been reported in the literature to play a major role in the genesis of lung cancer. The goal of this review is to summarize the common epigenetic changes associated with lung cancer to give some clarity to its etiology, and provide an overview of the potential translational applications of these changes, including applications for early detection, diagnosis, prognostication, and therapeutics.

show abstract

The expression of stem cell‐related indicators as a prognostic factor in human lung adenocarcinoma

Abstract: OCT4 and Bmi-1 may be good biomarkers to predict the prognosis of patients with completely resected lung adenocarcinoma.

Cited by 21 publications

References 55 publications

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy

Epigenetics of lung cancer

Contact Info

Product

Resources

About